Immucell (ICCC) Gross Margin (2010 - 2026)

Immucell (ICCC) has reported Gross Margin for 17 consecutive years, with 33.92% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin fell 981.0% year-over-year to 33.92%; the trailing twelve-month figure through Jun 2026 stood at 39.34% (up 190.0% YoY), and the FY2025 full-year result was 41.4%, up 1143.0% from the prior year.
• Gross Margin retreated to 33.92% in Q2 2026 per ICCC's latest filing, from 38.16% in the prior quarter.
• Across five years, Gross Margin topped out at 51.72% in Q1 2022 and bottomed at 8.73% in Q1 2023.
• Historically, Gross Margin has averaged 33.68% across 5 years, with a median of 35.22% in 2024.
• The sharpest annual moves came in 2023 and 2024: Gross Margin slumped 4300 bps in 2023, then surged 2290 bps in 2024.
• Over 5 years, Gross Margin stood at 25.37% in 2022, then retreated by 7 bps to 23.48% in 2023, then soared by 56 bps to 36.53% in 2024, then rose by 4 bps to 38.16% in 2025, then retreated by 11 bps to 33.92% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 33.92%, 38.16%, and 42.92% for Q2 2026, Q4 2025, and Q3 2025 respectively.